Xenin-25 Amplifies GIP-Mediated Insulin Secretion in Humans With Normal and Impaired Glucose Tolerance but Not Type 2 Diabetes
- Burton M. Wice1⇓,
- Dominic N. Reeds2,
- Hung D. Tran1,
- Dan L. Crimmins3,
- Bruce W. Patterson2,
- Judit Dunai1,
- Michael J. Wallendorf4,
- Jack H. Ladenson3,
- Dennis T. Villareal5,6 and
- Kenneth S. Polonsky1,7⇓
- 1Division of Endocrinology, Metabolism, and Lipid Research, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
- 2Division of Nutritional Science, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
- 3Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri
- 4Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri
- 5Division of Geriatrics, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
- 6Department of Geriatrics, University of New Mexico School of Medicine and New Mexico Veterans Affairs Health Care System, Albuquerque, New Mexico
- 7Division of Biological Sciences and Pritzker School of Medicine, The University of Chicago, Chicago, Illinois
- Corresponding author: Kenneth S. Polonsky, , or Burton M. Wice, .
Glucose-dependent insulinotropic polypeptide (GIP) potentiates glucose-stimulated insulin secretion (GSIS). This response is blunted in type 2 diabetes (T2DM). Xenin-25 is a 25–amino acid neurotensin-related peptide that amplifies GIP-mediated GSIS in hyperglycemic mice. This study determines if xenin-25 amplifies GIP-mediated GSIS in humans with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), or T2DM. Each fasting subject received graded glucose infusions to progressively raise plasma glucose concentrations, along with vehicle alone, GIP, xenin-25, or GIP plus xenin-25. Plasma glucose, insulin, C-peptide, and glucagon levels and insulin secretion rates (ISRs) were determined. GIP amplified GSIS in all groups. Initially, this response was rapid, profound, transient, and essentially glucose independent. Thereafter, ISRs increased as a function of plasma glucose. Although magnitudes of insulin secretory responses to GIP were similar in all groups, ISRs were not restored to normal in subjects with IGT and T2DM. Xenin-25 alone had no effect on ISRs or plasma glucagon levels, but the combination of GIP plus xenin-25 transiently increased ISR and plasma glucagon levels in subjects with NGT and IGT but not T2DM. Since xenin-25 signaling to islets is mediated by a cholinergic relay, impaired islet responses in T2DM may reflect defective neuronal, rather than GIP, signaling.
- Received October 13, 2011.
- Accepted February 29, 2012.
- © 2012 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.